Evidence map›Paper›PMID 22537248›Full record

ArticleBMC genomics2012

The stable traits of melanoma genetics: an alternate approach to target discovery.

Tara L Spivey, Valeria De Giorgi, Yingdong Zhao, Davide Bedognetti, Zoltan Pos, Qiuzhen Liu, Sara Tomei, Maria Libera Ascierto, Lorenzo Uccellini, Jennifer Reinboth and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Monoallelic expression in melanoma.Journal of translational medicine · 2019
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Melanoma NOS1 expression promotes dysfunctional IFN signaling.The Journal of clinical investigation · 2014
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Tara L SpiveyInfectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD 20892, USA.
Valeria De Giorgi
Yingdong Zhao
Davide Bedognetti
Zoltan Pos
Qiuzhen Liu
Sara Tomei
Maria Libera Ascierto
Lorenzo Uccellini
Jennifer Reinboth
Lotfi Chouchane
David F Stroncek
Ena Wang
Francesco M Marincola
National Institutes of Health Clinical Center · USImmungenetics (Germany) · DENational Institutes of Health · USSemmelweis University · HUUniversity of Würzburg · DEWeill Cornell Medical College in Qatar · QA

Funding

Immunogenetic Study of Infectious Diseases and CancerZIACL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2012
$0k
Develop novel assays for assessing cellular and gene therapiesZIACL002119 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2010 to 2025
$0k
6 · The paper itself

Abstract

backgroundThe weight that gene copy number plays in transcription remains controversial; although in specific cases gene expression correlates with copy number, the relationship cannot be inferred at the global level. We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number.

resultsFunctional interpretation of 3,030 transcripts concordantly expressed (Pearson's correlation coefficient p-value < 0.05) by CMs and TMs confirmed an enrichment of functions crucial to oncogenesis. Among them, 968 were expressed according to the transcriptional efficiency predicted by copy number analysis (Pearson's correlation coefficient p-value < 0.05). We named these genes, "genomic delegates" as they represent at the transcriptional level the genetic footprint of individual cancers. We then tested whether the genes could categorize 112 melanoma metastases. Two divergent phenotypes were observed: one with prevalent expression of cancer testis antigens, enhanced cyclin activity, WNT signaling, and a Th17 immune phenotype (Class A). This phenotype expressed, therefore, transcripts previously associated to more aggressive cancer. The second class (B) prevalently expressed genes associated with melanoma signaling including MITF, melanoma differentiation antigens, and displayed a Th1 immune phenotype associated with better prognosis and likelihood to respond to immunotherapy. An intermediate third class (C) was further identified. The three phenotypes were confirmed by unsupervised principal component analysis.

conclusionsThis study suggests that clinically relevant phenotypes of melanoma can be retraced to stable oncogenic properties of cancer cells linked to their genetic back bone, and offers a roadmap for uncovering novel targets for tailored anti-cancer therapy.

Indexed as

Gene Expression ProfilingMolecular Targeted TherapyCell Line, TumorGene DosageGenomicsHumansMelanomaRNA, MessengerSequence DeletionTranscription, GeneticRNA, Messenger

Identifiers

PMID22537248
PMCPMC3362771
OpenAlexW2158269414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.